Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Sacituzumab tirumotecan + Anlotinib in Advanced Driver-Negative NSCLC
ChiCTR2500111752Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate (ORR). Started Nov 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecananlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111752.